Redeye notes that Idogen has postponed the initiation of its phase I/II trial with IDO-8 in patients with hemophilia A. The trial, which was planned to commence in Q1 2021, is now delayed until H2 2021. While we find the postponed timeline discouraging, this is not a company-specific event, and we recognize that the corona pandemic is affecting the overall healthcare sector. Our base case valuation of SEK 8 per share remains unchanged following today’s news.